Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes
| Autor: | Hatice Nur Tarakcioglu, Ipek Tanir, Abdullah Ozkaya |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty Intraocular pressure Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors Dexamethasone Macular Edema 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Ophthalmology Ranibizumab Retinal Vein Occlusion medicine Humans Macular edema Glucocorticoids Intraocular Pressure Aged Retrospective Studies Drug Implants business.industry Retinal Middle Aged medicine.disease Treatment Outcome chemistry Intravitreal Injections 030221 ophthalmology & optometry Branch retinal vein occlusion Female Implant medicine.symptom business 030217 neurology & neurosurgery Tomography Optical Coherence Optometry medicine.drug |
| Zdroj: | Optometry and vision science : official publication of the American Academy of Optometry. 95(12) |
| ISSN: | 1538-9235 |
| Popis: | We compared the 24-month outcomes of ranibizumab and dexamethasone implants in treatment-naive branch retinal vein occlusion patients. Ranibizumab was effective in improving visual outcomes, whereas the dexamethasone implant was not.The aim of this study was to compare the 2-year real-world outcomes of intravitreal ranibizumab with dexamethasone implants in patients with macular edema secondary to branch retinal vein occlusion.The treatment-naive branch retinal vein occlusion patients with macular edema who were treated with intravitreal ranibizumab or dexamethasone implant were included retrospectively. Primary outcome measures were the change in best-corrected visual acuity and central retinal thickness.Eighty-seven eyes of 87 patients were included. Mean ± SD best-corrected visual acuity in the intravitreal ranibizumab group at baseline and 24 months was 0.64 ± 0.48 and 0.49 ± 0.44 logMAR (P.05). Mean ± SD best-corrected visual acuity in the intravitreal dexamethasone implant group at baseline and 24 months was 0.98 ± 0.56 and 0.92 ± 0.61 logMAR (P.05). Mean ± SD central retinal thickness in the intravitreal ranibizumab group at baseline and 24 months was 530 ± 150 and 337 ± 103 μm (P.05). Mean ± SD central retinal thickness in the intravitreal dexamethasone implant group at baseline and 24 months was 591 ± 113 and 335 ± 99 μm (P.05). Mean ± SD number of injections at 24 months was 5.6 ± 1.8 in the intravitreal ranibizumab group and 2.7 ± 1.1 in the dexamethasone implant group (P.0001). Progression in lens opacity was detected in 5.7% of the phakic patients in the intravitreal ranibizumab group and 46.1% of them in the dexamethasone implant group (P.0001). None of the patients in the intravitreal ranibizumab group and 9 (22.0%) of 41 patients in the dexamethasone implant group showed an increase of more than 10 mmHg in intraocular pressure.Ranibizumab was effective in the treatment of macular edema secondary to branch retinal vein occlusion in both visual and anatomical outcomes; however, dexamethasone implant was effective only in anatomical outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|